AMIDST AN INTERNATIONAL CANCER ADVOCACY, AN INSTITUTE IS BORN!

For Immediate Release – July 19, 2025

Global Alliance Launches THE INSTITUTE FOR MEN'S CANCERS to Promote Advancements in Clinical Diagnostics and Care

[7/22/2025- New York, NY] – In an exclusive round-table conference  between The Male Breast Cancer Global Alliance (MBCGA) and 6  executive members of  the Integrative Cancer Resource Society (ICRS), a discussion about the topmost challenging CANCERS worldwide is the main topic addressed.  This topic dovetailed to  the formation of the Institute for Men’s Cancers—a cornerstone initiative of their newly established global consortium. This new assembly unites leading clinical experts, researchers, and advocacy foundations to advance education, diagnostic innovation, and treatment strategies for all men’s cancers, including but not limited to prostate, testicular, and male breast cancer. Together, MBCGA and ICRS are driving a collaborative movement to address critical gaps in awareness, research, and equitable access to care of RARE MEN'S CANCERS worldwide.

The Institute is spearheaded by Dr. Lennard Goetze, President of F.A.C.E.S. (Firefighters Against Cancers and Exposures) and Executive Director of the ICRS. As a leading advocate for occupational and environmental cancer prevention, 

Joining the development initiative is Dr. Robert Bard, internationally recognized cancer imaging specialist and founder of the AngioInstitute. Elected earlier this year as Chair of MBCGA’s Diagnostic Health Committee, Dr. Bard now serves as the Institute’s Clinical Director, leading efforts to integrate advanced imaging protocols and personalized care strategies. With over three decades of pioneering diagnostic innovations, Dr. Bard is dedicated to expanding training programs and supporting clinics in regions where access to cutting-edge technology and protocols remains limited.

Mission Highlights

The initiatives of the Institute for Men's Cancers include:

• Global Training Programs: Establishing diagnostic and screening centers in underserved regions to empower local healthcare providers.

• Collaborative Research & Advocacy: Working alongside MBCGA CEO Cheri Ambrose to raise awareness, collect data on unreported cases, and advance personalized treatment models.

• Integrative Partnerships: Engaging both conventional and alternative treatment communities to explore synergistic solutions for men’s cancers.

• Policy & Outreach: Building relationships with national ambassadors, recruiting clinical advocates, and partnering with global health organizations to break through bureaucratic and political barriers.

“As a cancer institute, we believe advocacy and education must work hand-in-hand with research and patient care,” said Dr. Goetze. “This collaboration is about uniting diverse voices to pierce resistance and create a unified roadmap for global change.” Dr. Goetze brings his expertise in public health education to develop a comprehensive curriculum designed to map the current state of RARE male cancers and inspire actionable change.

Men's rare cancers include: 1) Penile Cancer: fewer than 1 in 100,000 men)d South America. 2) Male Breast Cancer: 1% of all breast cancers 3) Rare Prostate Cancers: neuroendocrine, glandular, basal cell, transitional cell, and sarcomas 4) Cutaneous T-cell Lymphoma (CTCL): rare skin malignancy is more often diagnosed in men, with Mycosis Fungoides being the most common subtype. 5) Germ Cell Tumors of the testicle are relatively rare, though their incidence appears to be increasing. 6) Sebaceous Carcinoma: This rare cancer arises from skin appendages and is more common in older, white males. 7) Kaposi Sarcoma: seen in older men of Jewish/Mediterranean descent 8) Ocular Melanoma: While rare, ocular melanoma is slightly more common in men and can occur as a spot on the iris or a freckle in the back of the eye. 9) Thyroid Cancers (rare for men) - Anaplastic thyroid cancer - Medullary thyroid cancer - Squamous cell carcinoma - Teratomas - Oncocytic (Hürthle cell) considered rare and more aggressive

A GLOBAL VOICE FOR MEDICAL CHANGE STARTS AT HOME

Through its far-reaching programs, the Institute aims to bring new visibility to men's cancers including those often-overlooked diseases —while serving as a catalyst for broader men’s cancer advocacy. By sharing critical data, enhancing statistics of care, and exploring solutions to improve outcomes, the Institute positions itself at the forefront of the next chapter in global cancer care.

4. Advocacy & Policy Taskforce
This taskforce will liaise with governments and international organizations to integrate RARE cancers into national cancer control plans.

This taskforce will liaise with governments and international organizations to integrate RARE cancers into national cancer control plans.

Public Voice, Global Reach Beyond her clinical practice, Dr. Mazza is a celebrated public speaker, a prolific medical educator, and the founder of HealthSpan Horizons—a health media platform and video production company committed to empowering global audiences with wellness education. Through interviews, virtual events, and high-engagement health segments, she brings medical science to life for both professionals and the public. Her content spans a wide range of vital topics—from hormone resilience and cancer prevention to regenerative medicine and functional testing. Her commanding media presence and relatable delivery style have made her a trusted voice in national campaigns—and now, a central figure in MBCGA’s expanded mission. “Dr. Mazza helps us amplify the message that bias and fear should never stop anyone from getting checked,” said Ambrose. “She bridges the gap between science and public understanding—and that’s the power we need to fight stigma and save lives.” (See complete feature on Dr. Mazza)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BUILDING A GLOBAL NETWORK FOR CHANGE

“Together, we can bring transformative awareness, break cultural and systemic barriers, and ensure every man has access to the care he deserves—no matter where he lives,” added Dr. Bard. For more information about The Institute for Men's Cancers or to explore partnership opportunities, visit MBCScan.com or contact press@MBCGA.org.

---

Founding Charter of the Institute for Men's Cancers

An Initiative of the Male Breast Cancer Global Alliance

Introduction: A Global Response to an Overlooked Crisis

The Institute for Men's Cancers is established in part as a dedicated subchapter of the Male Breast Cancer Global Alliance (MBCGA). It serves as a center for education, innovation, and action in the fight against RARE men's cancers.

As cancer remains needing of more support in screening and care in underserved areas worldwide, the Institute seeks to unify scientific research, diagnostic innovation, and public advocacy of men's cancers to join in a united initiative. It is designed to be an incubator of solutions—bringing together medical experts, policy leaders, educators, and patient advocates to reshape the narrative and response to men’s cancers worldwide.  The Institute operates under a singular vision: to ensure equitable access to knowledge, diagnostics, and care for men's cancers everywhere.

“To advance global awareness, foster diagnostic innovation, and drive education and research initiatives that improve outcomes for male cancers and men’s health at large.” We envision a world where all cancer is recognized, diagnosed early, and treated with cutting-edge, compassionate care—regardless of geography or socioeconomic status. Meanwhile, because specific men's cancers remain underreported, the focus of this initiative is to bring new resources to address these so-called RARE cancers in men.

Charter Overview: The Institute for Men’s Cancers is devoted to unifying caregivers, clinicians, researchers, and educators in a global mission to tackle the full spectrum of cancers that impact men. Our commitment embraces all men’s cancers—including, but not limited to, prostate, testicular, male breast, penile, bladder, kidney, and colorectal cancer—ensuring each disease area benefits from cutting-edge diagnostic protocols, personalized treatment pathways, and comprehensive education programs.

Our vision is to integrate clinical care, research, and education under a synergistic, multi disciplinary framework. We aim to:

1. Empower Healthcare Providers – Deliver standardized training in early detection, treatment innovations, and survivorship care to clinicians worldwide.

2. Drive Purposeful Research – Launch and support collaborative clinical trials, real world evidence collection, and translational studies that advance understanding and outcomes across the men’s cancer continuum.

3. Educate and Advocate – Develop curricula and public awareness campaigns that dismantle stigma, enhance health literacy, and encourage routine screening and proactive care in all communities.

Our Collaborative Mission

By fostering partnerships among medical institutions, advocacy organizations, community health centers, and global foundations, the Institute aims to:

• Bridge Gaps in Access to diagnostics, therapies, and information in underserved regions.

• Leverage Multi Cancer Insights so innovations in one domain—such as immunotherapy or precision medicine—benefit others.

• Amplify Clinical Excellence by connecting oncology, urology, radiology, pathology, endocrinology, mental health, and patient support teams under one shared agenda.

The Institute for Men’s Cancers represents a dedicated consortium focused on transforming men’s cancer care from fragmented silos into a cohesive, data driven movement—empowering every man with equitable, research backed, state of the art treatment.

Core Objectives

1. Global Education & Training:

o Develop and deploy training programs for healthcare providers, ensuring diagnostic and treatment excellence in regions with limited resources.

o Establish a digital education hub offering certifications, webinars, and curriculum for medical professionals.

2. Diagnostic Innovation:

o Promote access to non-invasive and cost-effective diagnostic tools, such as high-resolution ultrasound and thermal imaging, as frontline screening methods.

o Conduct pilot programs to implement diagnostic centers in underserved communities.

3. Research & Data Collection:

o Build a global registry of men's RARE cancer cases to address underreporting and improve epidemiological understanding.

o Partner with academic institutions for studies on alternative therapies and integrative approaches.

4. Advocacy & Outreach:

o Engage with policymakers, national health ministries, and global health organizations to prioritize cancer in public health agendas.

o Launch campaigns aimed at reducing stigma and increasing awareness of men’s cancers.

5. Global Partnerships:

o Collaborate with hospitals, NGOs, and community health systems to create sustainable programs.

o Form strategic alliances with technology developers and pharmaceutical leaders to bring innovations to the field.

Key Programs and Initiatives

1. The IMC Global Training Network

A flagship program designed to train clinicians, radiologists, and health workers in cancer detection and management.

• On-site and virtual workshops

• Development of region-specific protocols

• Certification for community-based healthcare providers

2. The Diagnostic Innovation Lab

A research hub focusing on validating and deploying novel diagnostic technologies that are cost-effective and scalable for low-resource settings.

3. The Global Cancer Data Initiative

A global data collection and analytics platform to document cases, track outcomes, and support policy recommendations.

4. Advocacy & Policy Taskforce

This taskforce will liaise with governments and international organizations to integrate RARE cancers into national cancer control plans.

See PA bill upgrade for public Cancer Screening

Outreach Strategy for Legislative Change

The Institute’s outreach model centers on inclusion, innovation, and impact.

• Community Engagement: Working with local leaders to adapt programs to cultural and regional needs.

• Media & Awareness Campaigns: Leveraging traditional and digital media to combat stigma and promote early detection.

• Partnership Development: Forming alliances with universities, NGOs, and private-sector innovators.

• Proposals for Local, State and National Partnerships: Forming a coalition with lawmakers to  promote updates in current legal bills about how cancer care is mitigated, managed and conducted.  

Commitment to Underserved Populations

A key pillar of the IMC is its focus on health equity. In many regions, barriers such as lack of infrastructure, outdated protocols, and cultural stigma hinder cancer detection and care. The Institute’s initiatives prioritize these underserved populations by:

• Providing diagnostic equipment and training at no cost through partnerships.

• Launching mobile diagnostic units for rural areas.

• Offering telehealth consultations and second opinions from Institute experts.

Long-Term Impact Goals (2025–2030)

• Establish 50+ training centers across five continents.

• Reach 100,000 healthcare professionals through virtual education platforms.

• Build a global RARE male cancer patient registry to improve epidemiological accuracy.

• Influence policy change in at least 25 countries to include RARE male cancers in national screening guidelines.

Closing Statement

The Institute for Men's Cancers stands as a bold and transformative initiative—combining science, education, and compassion to create a future where no man faces breast cancer in silence or isolation. By breaking barriers and uniting global efforts, the Institute embodies the power of collaboration in tackling one of healthcare’s most overlooked challenges.  “This is more than an institute. It’s a movement to redefine how the world sees, diagnoses, and treats male cancers including those that remain 'rare' simply due to lack of data.” – Dr. Lennard Goetze

 

Spotlight: Michael and Xio Caruso

Michael and Xio Caruso

On January 5, 2017, I was on the phone speaking with my daughter when I felt a tug around my chest and stood up to stretch. Suddenly I felt a lump behind my right nipple, which I never noticed during my morning showers. The very next morning my wife, Xio, called our doctor and made an appointment. I saw the doctor a week a later on January 12, and he gave me a full physical and sent me to the local hospital for a mammogram the next morning. Friday the 13^th will forever haunt me. Boy was that fun, not! I had no idea this is the torture women experience on an annual basis. Once it was over, and thank God it was, they told me I needed a biopsy. I was in a rush to get back to my office and did not want to wait around for insurance approval, so I told them to call me and I would return. By noon, they had approval and I was called back for the biopsy, where my wife joined me for my second round of torture. Little did I know I would have a “gentle” mammogram right after the biopsy.

I returned to work not thinking anything of it and the very next day my wife and I were on our way to join my parents in Florida for a week of fun in the sun. It was a three-day weekend, so I was told the results would be communicated to me on Tuesday. On Monday, January 16, I received my diagnosis after a call from our family doctor. There was no way to sugarcoat it, he said, “you have breast cancer”. I was just 49 years old. We sat around looking at each other with a collective feeling of shock. The doctor recommended three possible surgeons for me to see upon returning from vacation. One of them was Dr. Mark Gordon, an oncology surgeon who had treated my wife in the past for minor cysts. My wife immediately called his office and made an appointment for the following Monday. By the end of the day, I had a cancer patient navigator, and an appointment to see a genetics counselor. You see, my mother is a breast cancer survivor. I never did genetics testing because my sister tested negative, so I assumed it had skipped me. I was wrong!

I met with the genetics counselor first, and did my genetics test, then on to Dr. Gordon. He reviewed my pathology report and explained I had ductal carcinoma insitu. Dr. Gordon explained I needed surgery to remove the nipple and all the breast tissue, plus the layer of cells underneath and removal of sentinel lymph nodes (new vocabulary). Everything was moving fast. While waiting for the genetics results we made an appointment with my oncologist. She explained the possible treatment plan, chemo, radiation, and immunotherapy. I was diagnosed with triple positive, HER2 positive, Estrogen positive and Progesterone positive breast cancer. The genetics test confirmed I carried the BRACA-2 gene.

I had my surgery on Valentine’s Day, February 14, 2017. From mid-March until now, my treatment has consisted of chemo medications (Taxol, Adriamycin, Herceptin, and Perjeta to name a few), followed by radiation and now finishing my every three-week treatment of Herceptin and Perjeta. Tamoxifen has been added as a daily pill. I have a daughter who just turned 21 and will have her genetics test done as soon as possible to see if the BRACA-2 has been passed on to her.

Xio and I have made the decision to share my story with as many people we come across as possible in an effort to spread the word that men get breast cancer too. We have received amazing support from our respective employers, friends, and family, and cherish every little moment and milestones along the way. I just celebrated my 50^th birthday on April 3 with my relatives and closest friends and it was truly a celebration of life.

Our journey is not over, right before my big birthday celebration, Xio was diagnosed with a rare but treatable breast cancer, Mucinous Carcinoma (about 1% of women are diagnosed with this type of cancer).  I finished my last infusion on April 24^th, 2018, and she had her surgery in mid-May 2018. We are as prepared as two people can be to battle this dreaded disease. We joke we belong to the 1% club.

According to the American Cancer Society, about 2,550 new cases of invasive breast cancer in men will be diagnosed and many are not as lucky as me. For men, the lifetime risk of getting breast cancer is about 1 in 1,000. If you suspect something is wrong, in any part of your body, don’t ignore it and get it checked.

We have been honored to meet many fellow male breast cancer survivors and their families through organizations such as the Male Breast Cancer Coalition.  Since my diagnosis, we have had opportunities to participate in several events to raise awareness and will continue on that mission of awareness and advocacy.

Education and awareness are the key. Please share this information with your fathers, sons, uncles, brothers, cousins, grandfathers and every male in your lives (I do every chance I get). The fight against this disease can be won but it starts with spreading awareness. Men have breasts too!

 

Breast Cancer Risk in the Transgender and LGBTQ+ Community

Clinical Considerations in the Context of Hormone Replacement Therapy
By: Dr. Angela Mazza

Introduction

Breast cancer is often thought of as a disease that only affects cisgender women, but the truth is: anyone with breast tissue can get breast cancer. That includes transgender women, transgender men, nonbinary people, and lesbian, gay, and bisexual individuals. This article is here to help you understand the facts, especially if you're part of the LGBTQ+ community or taking gender-affirming hormones.

How Hormones Affect Breast Cancer Risk
Hormone therapy is a powerful, gender-affirming treatment that supports many people in living as their true selves. It also changes how your body works, including how breast tissue develops. Here’s what the research shows:

• Transgender women (assigned male at birth, AMAB) who take estrogen grow breast tissue. Long-term estrogen use may raise the risk of breast cancer, especially after 5 to 10 years. Studies show their risk is higher than cisgender men but still lower than cisgender women [1].

• Transgender men (assigned female at birth, AFAB) who take testosterone may have less breast tissue, which can lower their risk. But if they haven't had top surgery (or if some breast tissue remains after surgery), there is still some risk [2].

• Nonbinary people may or may not use hormones, and their risk depends on whether they have breast tissue and what kind of hormones they take.

It’s important to know: hormones are not dangerous—they are life-saving for many people. But like all medical treatments, they should be monitored over time.

Other Risk Factors to Know
You may also be at higher risk if:

• You smoke or drink alcohol often

• You have a family history of breast cancer

• You are overweight or obese

• You haven’t been pregnant or breastfed

These are common factors in the general population, but some may be more common in LGBTQ+ communities due to stress, discrimination, or lack of access to affirming healthcare [3,4].

Why Screening Matters
Regular screening can catch breast cancer early, when it's easier to treat. But many LGBTQ+ people avoid doctors due to past bad experiences, misgendering, or fear of discrimination. That’s why inclusive, respectful care is so important.

You may need screening if:

• You have breast tissue and are over age 40

• You’ve been on estrogen for over 5 years

• You have a family history of breast or ovarian cancer

Talk to a provider you trust about what screenings (like mammograms or ultrasounds) make sense for your body and your history.

How to Protect Your Health

• Find a provider who respects your gender identity and listens to your concerns.

• Share your hormone and surgical history so they can guide you on screening.

• Don’t wait to speak up if you notice changes in your chest or breasts, like lumps or nipple discharge.

• Advocate for yourself. You deserve care that sees and affirms you.

Conclusion
Breast cancer doesn’t care about gender identity or sexual orientation. What matters is that you know your risk, stay informed, and get care that respects who you are. Hormones are part of a healthy, affirming life for many—but understanding how they affect your body is an important step in caring for yourself. You deserve to feel safe, seen, and supported in every doctor’s office you walk into.

...................................................................................................................................................................

“A Wake-Up Call for Gender-Specific Cancer Care” By Robert L. Bard, MD – Chair of Clinical Diagnostics, MBCGA

As a diagnostic imaging specialist, I have spent decades studying the pathways of cancer—how it develops, how it spreads, and most importantly, how it responds to treatment across diverse patient populations. This work has exposed a critical flaw in our system: despite clear biological differences, men and women are too often treated as interchangeable in cancer care.

What Dr. Jose Pablo Leone is accomplishing with the ETHAN trial is groundbreaking because it directly challenges this outdated paradigm. For decades, endocrine therapies were designed and tested almost exclusively in women, then applied to male breast cancer patients with minimal data. This has led to unpredictable outcomes and, in many cases, severe and unnecessary toxicities.

In my role with the Male Breast Cancer Global Alliance, I’ve met countless male patients who suffer debilitating side effects from therapies never optimized for their physiology. Men metabolize drugs differently, and their hormonal environment—characterized by higher androgen levels—alters both efficacy and tolerability. For example, aromatase inhibitors in men without gonadal suppression may fail to achieve sufficient estrogen blockade, while tamoxifen often produces more profound sexual dysfunction and thrombotic risks. These are not minor variations; they are fundamental biological differences that demand tailored solutions.

The ETHAN trial embraces this challenge by investigating endocrine strategies specifically in male breast cancer, including the use of gonadal suppression and CDK4/6 inhibitors. It gives us a chance to understand not only which treatments control tumors but which minimize collateral damage to quality of life—a factor too often sidelined in oncology.

It’s time for a cultural and scientific shift. Gender-specific research must become the standard, not the exception. ETHAN stands as a model of how we can advance precision medicine and equity simultaneously. It reminds us that treating men based on female-centric data is no longer acceptable in a field striving for excellence. We owe every patient—not just the majority—the dignity of evidence-based care.

Male Breast Cancer’s Hidden Mental Health Crisis

By: Dr. Barbara Bartlik

Male breast cancer remains one of the most misunderstood and underdiscussed diagnoses in oncology. For integrative psychiatrist Dr. Barbara Bartlik, the silence surrounding men’s emotional and sexual health in the wake of cancer is a gap that demands urgent attention. Her holistic perspective challenges the status quo and offers hope for survivors navigating the complex terrain of healing.

When most people think of breast cancer, they imagine women fighting a disease that has become a rallying cry for global awareness. But for men, who make up a small yet significant percentage of breast cancer diagnoses, the reality is different—quieter, lonelier, and often laden with stigma.

“Most men keep it very quiet. They don’t share it. They’re embarrassed about it because it seems to be a woman’s problem,” says Dr. Bartlik. This isolation leaves male survivors adrift in a healthcare system that is rarely designed with their unique needs in mind.

As an integrative psychiatrist, Bartlik occupies a rare position at the intersection of physical and mental health. Her work goes beyond traditional talk therapy, encompassing clinical insight into how cancer treatments impact the body, mind, and relationships. “You’re not just therapists at that level,” she explains. “You’re also clinical. That means understanding the real effects of treatments like Tamoxifen, which are killing the sex drive, damaging the immune system, and leaving patients depressed—even suicidal.”

 

The Andropause of Cancer Treatment

Tamoxifen, a mainstay in breast cancer care, is central to Bartlik’s concerns. Commonly prescribed to male survivors post-surgery, it effectively induces a chemical andropause—akin to menopause in women. “They may experience hot flashes, mood swings, fatigue, depression, and a complete loss of libido,” she says. “It’s a long haul because they often have to be on it for five years, sometimes more. Most people do not like Tamoxifen. They’ve lost their energy, and it’s a very unpleasant feeling.”

For many men, these side effects strike at the core of their identity, compounding feelings of shame and alienation. Unlike women, who have networks of support groups and survivor organizations, men with breast cancer often navigate their journey in solitude. “Women have organizations where they can meet with other survivors. But for men, there’s very little support out there. They may never meet another man who has breast cancer,” Bartlik explains.

This profound sense of isolation is not just an emotional issue—it’s a public health concern. Without adequate mental health support, survivors may spiral into depression, anxiety, or worse. “Cancer in itself is a downturn for a person. It makes everything so bleak. Even just trying to survive it—the depression, the PTSD—it’s massive,” she adds.

 

 

A Call for Holistic Intervention

Dr. Bartlik believes the traditional oncology model, focused on eradicating tumors, often overlooks these critical aspects of healing. “Surgeons and oncologists are focused on killing the cancer. They may not think about bringing in a psychiatrist or helping support the man in adjusting to this new way of life—living with low testosterone, for instance.”

Her approach involves more than just medication. Bartlik incorporates nutritional strategies and natural supplements designed to mitigate some of the sexual and mood-related side effects of cancer treatment. “There are supplements like ginkgo biloba and tribulus to boost sex drive, long jack for erectile function, and amino acids like L-arginine and citrulline that open blood vessels. Magnesium helps too, because it relaxes and opens blood vessels.”

However, she underscores the importance of collaboration. “We have to work with the oncologist because some of these supplements can increase testosterone, and that’s not desirable in certain cases.” This careful balance reflects her integrative philosophy: treating the whole person, not just the disease.

 

Sexual Health as Mental Health

Beyond Tamoxifen, Bartlik highlights how other cancer treatments further complicate male sexual health. “We’re talking about testosterone blockers in men with prostate cancer and surgeries that inevitably affect sexual functioning,” she explains. “Some men are lucky and can retain some of it, but for others, the changes are devastating.”

She notes that early post-surgical interventions can make a difference. “If you take Cialis a month after surgery and continue daily, it can help blood flow and possibly restore some function.” For men struggling with lingering dysfunction, Bartlik’s protocols include both pharmacological aids and natural remedies.

“Sexual health is mental health,” she emphasizes. “When these men lose their sexual identity, it impacts their relationships, their mood, and their overall quality of life. Addressing this is not optional—it’s essential.”

 

Breaking the Stigma

For Bartlik, male breast cancer advocacy is more than a professional interest—it’s a mission. She sees an urgent need to break through stigma and silence, empowering men to seek help without shame. “Pursuing clinical care for men with breast cancer is a huge platform I didn’t even think about until I started realizing how sexual health and depression are all over cancer care—and specifically men’s cancer.”

Collaborations with advocacy groups and publishing her insights could amplify this message. “This is an area where we can make a huge difference in men’s health. It’s lifesaving work—because killing the stigma is just as important as killing the cancer.”

 

Toward a New Standard of Care

As she reflects on her role, Dr. Bartlik envisions a future where psychiatry is woven seamlessly into oncology care for men. “These patients are dealing with far more than just physical illness. They’re coping with loss—of health, of identity, of intimacy. Our job is to help them heal in every sense of the word.” For the men still suffering in silence, her message is clear: help exists, and they are not alone. With the right support, recovery can be about more than survival—it can mean reclaiming a full, vibrant life.

----------------------------------------------------------------------------------------------------------------------------

ABOUT THE AUTHOR

Dr. Barbara Bartlik is a renowned integrative psychiatrist with over three decades of clinical experience, specializing in the intersection of mental health, sexual health, and functional medicine. Board-certified in psychiatry and a fellow of the American Psychiatric Association, she is celebrated for her holistic approach to treating trauma, anxiety, depression, and sexual dysfunction.  As an editor of Integrative Sexual Health (a volume in Dr. Andrew Weil’s Integrative Medicine Library), Dr. Bartlik brings academic rigor to her innovative work. She integrates lifestyle medicine, nutritional strategies, and mind-body therapies into psychiatric care, helping patients achieve transformative healing.

A sought-after speaker and media contributor, she addresses audiences worldwide on topics from PTSD recovery to menopause and andropause support. Based in Manhattan, Dr. Bartlik continues to redefine mental health care for the modern age—bridging science, compassion, and whole-person wellness.

“Saving Our Guys”: Pennsylvania’s HB433 and the Fight for Male Breast Cancer Awareness

Written & Edited by: Dr. Roberta Kline & Graciella Davi, PhD

In a landmark moment for public health and gender-inclusive cancer care, Pennsylvania’s HB433 passed the House with a resounding 197–5 vote. This legislative victory marks a critical step toward dismantling the pervasive silence surrounding male breast cancer. In a recent virtual meeting with House Representative Gina H. Curry, advocates and survivors gathered to reflect on the bill’s impact and chart new strategies for expanding awareness and access to diagnostic care.

The meeting, spearheaded by Cheri Ambrose of the Male Breast Cancer Global Alliance (MBCGA), featured survivors Stephen Sala and Garry Davis, diagnostic imaging specialist Dr. Robert Bard, and MBCGA’s education director Lennard Goetze. Together, they shared powerful stories and expert insights, weaving a narrative of urgency and hope.

Humanizing the Statistics: Two Survivors Speak Out
Stephen Sala, now nine years cancer-free, discovered his diagnosis almost by accident. “I was just looking in the mirror and a lump popped out on my chest,” he recalled. Despite his proactive approach and familiarity with cancer support networks, Sala was initially met with dismissiveness from his primary care physician. It wasn’t until further testing that the true severity became clear. “I had a double mastectomy. The cancer didn’t show on a mammogram, but when they went in, they found it early in my other breast as well.”

Garry Davis’s journey, by contrast, reflects the high stakes of late detection. Diagnosed at 58 after his wife noticed a lump during a casual moment at home, Davis’s cancer had already metastasized to his bones. “I didn’t even know men could get breast cancer,” Davis said. “It wasn’t on my radar. My primary doctor never recommended an exam, and by the time we found it, surgery wasn’t an option.” Now four and a half years into living with Stage 4 disease, Davis embodies resilience, undergoing treatments while advocating for others to get checked.

These stories echo a sobering national truth: while male breast cancer accounts for less than 1% of all breast cancers, the American Cancer Society estimates approximately 2,800 new cases and 530 deaths in U.S. men annually. Men of color are disproportionately affected. Studies indicate Black men have a 52% higher mortality rate from breast cancer than their white counterparts, underscoring systemic disparities in education, access, and outcomes.

Dr. Bard: Pioneering Non-Invasive Diagnostics
As male survivors like Sala and Davis continue to speak out, medical professionals such as Dr. Robert Bard are working to revolutionize early detection. With decades of experience in advanced diagnostic imaging, Bard advocates for alternatives to traditional mammography—particularly ultrasound and thermography. “Men won’t go for a mammogram, but they will come in for a sonogram or thermogram. It’s quick, painless, and preserves dignity,” Bard explained.

His emphasis on non-invasive screening resonates in underserved communities, where cultural stigma and financial barriers often deter men from seeking care. Bard’s work with high-risk groups such as firefighters exposed to carcinogens has shown how environmental toxins can accelerate cancers in both men and women. “We’re seeing younger patients. Early screening isn’t optional anymore—it’s essential,” he warned.

Bard also highlighted the dual benefits of thermal imaging, which not only detects breast anomalies but can also reveal cardiovascular issues like pre-stroke conditions—a critical consideration for men, who statistically underutilize preventive healthcare.

HB433: A Legislative Game Changer
Pennsylvania’s HB433, championed by Rep. Curry, is designed to expand insurance coverage for diagnostic breast imaging following an abnormal screening mammogram. The bill addresses a long-standing gap in care where insurance plans often covered screening but not the diagnostic follow-ups needed to confirm or rule out cancer—leaving patients with out-of-pocket costs ranging from $1,000 to $4,500.

For men, this financial barrier can be especially devastating. Awareness of male breast cancer remains so low that many men delay care until symptoms are advanced, making affordable diagnostic options crucial. “This legislation isn’t just about cost. It’s about saving lives through earlier detection,” Curry emphasized during the meeting.

The bill’s passage in the House reflects growing recognition of these issues. However, Curry noted challenges ahead in the Senate, particularly resistance from insurance federations wary of expanded coverage mandates. Despite these hurdles, she expressed optimism. “With support from advocates like MBCGA and survivors willing to tell their stories, we can keep the momentum going.”

The Role of Advocacy: Breaking Bias and Building Awareness
Bias remains a formidable obstacle. Lennard Goetze underscored how societal perceptions hinder men’s health-seeking behaviors. “Men don’t even want to admit they have breast tissue, let alone cancer. Part of our campaign—‘Drop the Bias’—aims to challenge that mindset and encourage men to take ownership of their health.”

Ms. Ambrose added, “The language of legislation matters. It shouldn’t just say ‘women’s health.’ This is about people’s health. Changing that wording changes lives.”

Survivor Stephen Sala’s local advocacy in Philadelphia offers a model for grassroots impact. After sharing his story on social media and local news, he heard from numerous men who sought screening as a direct result. “It’s all about raising awareness. Most men aren’t being checked during physicals, and we need to change that,” he said.

Addressing Racial Disparities in Care
Rep. Curry, reflecting on her own family’s experiences, voiced concern about racial disparities in men’s health. “Particularly Black men—they’re not seeing retirement. They’re not seeing grandchildren. We have to save our guys.”

Her commitment extends to speaking at upcoming conferences for state legislators, including the National Black Caucus of State Legislators. “We know these diseases hit Black communities 40 to 50 times harder. That’s where we need to focus outreach.”

A Vision for the Future
As the meeting concluded, there was consensus on the need for continued collaboration. Dr. Bard invited Rep. Curry to visit his New York office to see diagnostic technologies firsthand. Ambrose and Goetze pledged to support Curry’s efforts in Pennsylvania and beyond.

“This isn’t just about Pennsylvania,” Goetze noted. “It’s about setting a precedent for other states and eventually federal policy.”

________________________________________

Summary: Momentum Toward Change
Pennsylvania’s HB433 represents more than a legislative victory—it’s a clarion call to address a long-overlooked health crisis. By elevating male voices, pioneering new diagnostics, and advocating for equitable policies, leaders like Senator Curry and organizations like MBCGA are reshaping the landscape of breast cancer care.

As Garry Davis put it, “I thought this was a women’s disease. I know better now. And I want other men to know too—before it’s too late.”

Defining Cancer Alliance: 2025

Written b:y Cheri Ambrose for the Integrative Cancer Resource Society

"You can’t build a movement alone—you build it one relationship, one conversation, one act of courage at a time."

When I launched my journey into cancer advocacy 15 years ago, I could never have imagined where it would lead. What began as a mission to give voice to the underserved has become a global calling—to unite survivors, caregivers, researchers, clinicians, and visionaries in a fight far greater than any of us could wage alone. This is the essence of alliance building.

It’s not about titles or accolades—it’s about connecting human beings across borders, disciplines, and differences to create solutions that save lives.

The Heart of an Alliance

Alliance building, at its core, is about trust. It’s about reaching out to a stranger on LinkedIn and discovering a shared passion. It’s about sitting in hotel conference rooms until midnight hammering out survivor support strategies. It’s about leaning into hard conversations and finding common ground where none seemed possible.

Social media has been my bridge to the world. Platforms like LinkedIn have helped me discover allies on every continent—doctors in Portugal, advocates in Australia, survivors in Africa—each bringing their unique brilliance to the cause. Through these virtual handshakes, we’ve sparked joint webinars, co-authored white papers, and built survivor networks that transcend oceans.

"The beauty of an alliance is that it grows stronger with every voice added."

This synergy isn’t theoretical. It’s tangible. A single introduction can lead to a global awareness campaign. A single Zoom call can turn into a transcontinental research initiative.

Milestones and Moments

This year has been a testament to what alliances can accomplish.

In March 2025, I was humbled to receive the Heart of Advocacy Award from the National Consortium of Breast Centers at their annual conference in Las Vegas. As I stood before hundreds of breast health professionals, I realized this honor wasn’t just mine—it belonged to every survivor who shared their story, every clinician who said “yes” to collaboration, and every advocate who refuses to give up.

We’re keeping the momentum going with events that matter:

• October 6: Our 3rd Annual All Boobs Matter event with Mike Landesberg on Long Island continues breaking stigma and sparking conversations about male and female breast cancer alike.

• September 17–19: The American Cancer Society Round Table in Washington brought together policymakers and medical leaders to reimagine patient care pathways.

• November 6–8: I’ll join colleagues at the ABC8 Advanced Breast Cancer Global Alliance Conference in Lisbon, Portugal, where international dialogue drives local action.

• December 10–12: The San Antonio Breast Cancer Symposium, the largest in the U.S. with 30,000 participants, is where science and advocacy meet at scale.

One event especially close to my heart was produced by my friend Vicki Durston of the WHO Global Breast Cancer Initiative and Breast Cancer Network Australia. Seeing Dr. Clifford Hudis, CEO of ASCO, in attendance reminded me that when giants gather, ripples turn into waves. At the “Showcasing BCNA’s Consumer-Led Advocacy for Visibility of Metastatic Breast Cancer” event in New York City, hosted by the American Australian Association, Vicki Durston, Director of Policy, Advocacy and Support Services at Breast Cancer Network Australia (BCNA), reflected on the power of international collaboration. The gathering united Australian and New York advocates to amplify breast cancer awareness and share innovative approaches to patient support.

Durston emphasized the importance of empowering individuals through BCNA’s training programs, which have equipped consumer representatives to share their stories and drive change. “This event exemplified how our collective passion can drive impactful actions that resonate globally, ensuring every voice is heard and every experience valued,” she said. Partnering with leaders from ASCO, Metavivor, Touch, and the Male Breast Cancer Global Alliance underscored the shared commitment to improving the lives of those affected by metastatic breast cancer worldwide.

"Alliances are born in small rooms, on late-night calls, and in shared visions for something better."

 

My Medical Advisory Board: Proof of What’s Possible

No alliance can succeed without experts willing to lean in. I am deeply proud of the MBC Global Alliance Medical Advisory Board—a dream team of brilliant minds and compassionate hearts:

• Dr. Robert Bard, a diagnostic imaging pioneer whose work with ultrasound has advanced early detection for male breast cancer.

• Dr. Fatima Cardoso, a champion for metastatic breast cancer patients worldwide.

• Dr. Oliver Bogler, who inspires with his unique perspective as both a researcher and male breast cancer survivor.

• Dr. Ben Ho Park, whose precision oncology work is rewriting what personalized medicine means.

• Dr. Pablo Leone, whose leadership in clinical trials like ETHAN reflects our shared commitment to gender-inclusive cancer research.

Together, they represent the strength of multidisciplinary collaboration—the very soul of alliance building.

THE GIFT OF GET-TOGETHERS  In today’s era of Zoom fatigue and digital-only dialogues, nothing rivals the substance of in-person gatherings. Conferences like the ABC Global Alliance’s Advanced Breast Cancer Seventh International Consensus Conference (ABC7), held November 9‑11, 2023, in Lisbon, serve as powerful proof. With over 1,200 participants from nearly 90 countries—clinicians, researchers, advocates, nurses, patients, industry representatives, and policymakers—ABC7 was a melting pot of perspectives and expertise.  Key themes included the latest in endocrine resistance, anti-HER2 therapies for brain metastases, and equitable clinical trial practices. The “Inclusion by Design” poster series and workshop convened stakeholders to discuss improving diversity in trials through 16 actionable recommendations . But the true value was in the hallway conversations and table‑side insights. Over coffee and sit-downs, a researcher exploring endocrine resistance formed a partnership with an advocate passionate about patient education. A clinician from South America connected with a nursing leader from Australia to co-develop support tools. These spontaneous moments often sparked collaborative research proposals and advocacy campaigns across borders. As Cheri Ambrose of the Male Breast Cancer Global Alliance observed, “These gatherings are where we see the true magic of alliance‑building—where every story shared and every handshake exchanged strengthens our global fight against cancer.”  Physical get‑togethers like ABC7 aren’t just events—they’re the crucibles of meaningful alliances, the starting point for innovation, empathy, and action that transform global care.

Why Alliances Matter

Cancer doesn’t discriminate, and neither can we. As advocates, we must build bridges between silos—bridges between survivors and scientists, between policy and practice, between local communities and global networks.

We need alliances to:
✔ Advance gender-inclusive cancer research.
✔ Build survivor networks across continents.
✔ Push for legislation that ensures equitable screening and treatment.
✔ Educate clinicians about rare and underserved cancer populations.

"Alliance building is action. It’s not a meeting or a mission statement—it’s the work of bringing people together to rewrite the future."

A Call to Action

To every survivor, clinician, policymaker, and advocate reading this: we need you. Your voice, your ideas, your willingness to collaborate. This isn’t just about male breast cancer. It’s about transforming cancer care for everyone.

If you’ve ever felt like one person can’t make a difference, let me assure you: you can. Because alliances are built one relationship at a time.

And when we come together, there is no limit to what we can achieve.

About the Author

Cheri Ambrose is the founder and president of the Male Breast Cancer Global Alliance, an international advocacy network dedicated to raising awareness, improving research, and supporting survivors of male breast cancer. With over 15 years of experience in patient advocacy, Cheri has become a recognized leader in forging partnerships between survivors, clinicians, researchers, and policymakers. She is the recipient of the 2025 Heart of Advocacy Award from the National Consortium of Breast Centers and continues to champion global efforts for gender-inclusive cancer care.